Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

EDSA US Equity

Edesa Biotech, Inc.Health Care · Pharmaceutical Preparations · CIK 1540159 · FY ends Sep 30
$5.75
+0.04 (+0.70%)
USD · as of 2026-08-19 · marketstack

EDSA · 10-K · period ended 2020-09-30

← all EDSA documents
filed 2020-12-07 · EDGAR original ↗

Our rendering of the filing — original pagination and typography are not reproduced, and tables are reduced to their short label cells (the figures live on FA). Nothing is summarized: every line below is the filing's own text.

blocks 1,4242,023 of 5,968309k characters rendered

Item 1A.RISK

FACTORS.

Certain factors may have

a material adverse effect on our business, prospects, financial

condition and results of operations. You should carefully consider

the risks and uncertainties described below together with all of

the other information contained in this Annual Report on Form 10-K,

including our financial statements and the related notes, before

deciding to invest in our common shares. The risks and

uncertainties described below are not the only ones we face.

Additional risks and uncertainties not presently known to us or

that we currently believe to be immaterial may also adversely

affect our business. If any of the following risks actually occurs,

our business, financial condition, results of operations and future

prospects could be materially and adversely

affected.

Risks Related to Our Business

We have incurred significant losses since our inception and expect

to continue to incur losses and may never generate profits from

operations or maintain profitability.

Since

inception, we have incurred significant operating losses. As of

September 30, 2020, we have an accumulated deficit of $13.1

million. We have historically financed operations primarily through

issuances of common shares, the exercise of common share purchase

warrants, convertible preferred shares, convertible loans,

government grants and tax incentives. We have devoted substantially

all of our efforts to research and development, including clinical

trials, and have not completed the development of any of our drug

candidates.

We expect to continue to incur significant expenses and operating

losses for the foreseeable future as we continue the development

of, and seek marketing approvals for our product candidates,

prepare for and begin the commercialization of any approved

products, and add infrastructure and personnel to support our

product development efforts and operations as a public company in

the United States and Canada. The net losses we incur may fluctuate

significantly from quarter to quarter and year to

year.

Based on our current plans, we do not expect to generate

significant revenue unless and until we or a current or potential

future licensee obtains marketing approval for, and commercializes,

one or more of our product candidates, which may require several

years. Neither we nor a licensee may ever succeed in obtaining

marketing approval for, or commercializing our product candidates

and, even if marketing approval is obtained, we may never generate

revenues that are significant enough to generate profits from

operations.

15

We will need substantial additional funding to finance our

operations through regulatory approval of one or more of our

product candidates. If we are unable to raise capital when needed,

we could be forced to delay, reduce or eliminate our product

development programs or commercialization efforts.

We expect our research and development expenses to increase

substantially in the future, particularly if we advance any drug

candidates beyond Phase 2 clinical development or expand the number

of drug candidates in clinical studies. In addition, if we obtain

marketing approval for any of our product candidates that are not

then subject to licensing, collaboration or similar arrangements

with third parties, we expect to incur significant

commercialization expenses related to product sales, marketing,

distribution and manufacturing. If we are unable to raise capital

when needed, or on attractive terms, we could be forced to delay,

reduce or eliminate research and development programs or future

commercialization efforts.

We depend heavily on the success of our drug product candidates. If

we are unable to obtain regulatory approval or commercialize one or

more of these experimental treatments, or experience significant

delays in doing so, our business will be materially

harmed.

Our ability to generate product revenues, which may not occur for

multiple years, if at all, will depend heavily on the successful

development and commercialization of our drug product candidates.

The success of our product candidates will depend on a number of

factors, including the following:

our ability to obtain additional capital from potential future

licensing, collaboration or similar arrangements or from any future

offering of our debt or equity securities;

our ability to identify and enter into potential future licenses or

other collaboration arrangements with third parties and the terms

of the arrangements;

our timing to obtain applicable regulatory approvals;

successful completion of clinical development;

the ability to provide acceptable evidence demonstrating a product

candidates’ safety and efficacy;

receipt of marketing approvals from applicable regulatory

authorities and similar foreign regulatory

authorities;

the availability of raw materials to produce our product

candidates;

obtaining and maintaining commercial manufacturing arrangements

with third-party manufacturers or establishing commercial-scale

manufacturing capabilities;

obtaining and maintaining patent and trade secret protection and

regulatory exclusivity;

establishing sales, marketing and distribution

capabilities;

generating commercial sales of the product candidate, if and when

approved, whether alone or in collaboration with

others;

acceptance of the product candidate, if and when approved, by

patients, the medical community and third-party

payors;

effectively competing with other therapies; and

maintaining an acceptable safety profile of the product candidate

following approval.

If we do not achieve one or more of these factors in a timely

manner or at all, we could experience significant delays or an

inability to successfully commercialize any of our product

candidates, which would materially harm our business. Many of these

factors are beyond our control. Accordingly, we may never be able

to generate revenues through the license or sale of any of our

product candidates.

Public health threats could have an adverse effect on our

operations and financial results.

Public health threats could adversely affect our ongoing or planned

research and development activities, particularly SARS-CoV-2 (which

causes the disease now called COVID-19). The outbreak of COVID-19

has severely impacted global economic activity and caused

significant volatility and negative pressure in financial markets.

The global impact of the outbreak has been rapidly evolving and

many countries, including the United States, have reacted by

instituting quarantines, mandating business and school closures and

restricting travel. As a result, the COVID-19 pandemic is

negatively impacting almost every industry directly or indirectly.

We cannot presently predict the scope and severity of any potential

business shutdowns or disruptions, but if we or any of the third

parties with whom we engage, including the suppliers, clinical

trial sites, regulators and other third parties with whom we

conduct business, were to experience shutdowns or other business

disruptions, our ability to conduct our business in the manner and

on the timelines presently planned could be materially and

negatively impacted. Global epidemics, such as the coronavirus,

could also negatively affect site activation, as well as

recruitment and retention, at sites in a region or city whose

health care system becomes overwhelmed due to the illness, which

could have a material adverse effect on our business and our

results of operation and financial condition.

16

Our limited

operating history may make it difficult for you to evaluate the

success of our business to date and to assess our future

viability.

Our primarily operating entity, Edesa Biotech Research, Inc. was

formed in July 2015. To date, our operations have been limited to

organization and staffing, developing and securing our technology,

entering into licensing arrangements, raising capital and

undertaking preclinical studies and clinical trials of our product

candidates. We have not yet demonstrated our ability to

successfully complete development of any product candidate, obtain

marketing approval, manufacture a commercial scale product, or

arrange for a third-party to do so on our behalf, or conduct sales

and marketing activities necessary for successful product

commercialization. Assuming we obtain marketing approval for any of

our product candidates, we will need to transition from a company

with a research and development focus to a company capable of

supporting commercial activities. We may encounter unforeseen

expenses, difficulties, complications and delays and may not be

successful in such a transition. Any predictions made about our

future success or viability may not be as accurate as they could be

if we had a longer operating history.

We may not be successful in our efforts to identify and acquire or

in-license additional product candidates.

Part of our strategy involves diversifying our product development

risk by identifying and acquiring or in-licensing novel product

candidates. We may fail to identify and acquire or in-license

promising product candidates. The competition to acquire or

in-license promising product candidates is fierce, especially from

large multinational companies that have greater resources and

experience than we have. If we are unable to identify and acquire

or in-license suitable product candidates, we will be unable to

diversify our product risk. We believe that any such failure could

have a significant negative impact on our prospects because the

risk of failure of any particular development program in the

pharmaceutical field is high.

We may expend our limited resources to pursue a particular product

candidate and fail to capitalize on product candidates that may be

more profitable or for which there is a greater likelihood of

success.

Because we have limited financial and managerial resources, we

focus on specific product candidates. As a result, we may forego or

delay pursuit of opportunities with other product candidates that

later could prove to have greater commercial potential. Our

resource allocation decisions may cause us to fail to capitalize on

viable commercial products or profitable market opportunities. If

we do not accurately evaluate the commercial potential or target

market for a particular product candidate, our business may be

negatively impacted.

Our future success depends on our ability to retain key executives

and to attract, retain and motivate qualified

personnel.

We are highly dependent on Dr. Pardeep

Nijhawan, our Chief Executive Officer and Secretary; and Michael

Brooks, our President; as well as other principal members of our

management and scientific teams. Although we have employment

agreements with each of our executive officers, these agreements do

not prevent our executives from terminating their employment with

the company at any time. The unplanned loss of the services of any

of these persons could materially impact the achievement of our

research, development, financial and commercialization objectives.

Recruiting and retaining qualified personnel, including in the

United States and Canada, will also be critical to our success. We

may not be able to attract and retain these personnel on acceptable

terms given the competition among numerous biotechnology and

pharmaceutical companies for similar personnel. In addition, we

rely on consultants and advisors, including scientific and clinical

advisors, to assist us in formulating our research and development

and commercialization strategy. Our consultants and advisors may

have commitments with other entities that may limit their

availability to us.

We expect to expand our capabilities, and as a result, we may

encounter difficulties in managing our growth, which could disrupt

our operations.

We expect to experience growth in the number of our employees and

the scope of our operations, particularly in the areas of drug

development, regulatory affairs, finance and administration and,

potentially, sales and marketing. To manage our anticipated future

growth, we must continue to implement and improve our managerial,

operational and financial systems, expand our facilities and

continue to recruit and train additional qualified personnel. We

may not be able to effectively manage the expansion of our

operations or recruit and train additional qualified personnel. The

physical expansion of our operations may lead to significant costs

and may divert our management and business development resources.

Any inability to manage growth could delay the execution of our

business plans or disrupt our operations.

17

We are exposed to risks related to currency exchange

rates.

We conduct a significant portion of our operations outside of the

United States. Because our financial statements are presented in

U.S. dollars, changes in currency exchange rates have had and could

have in the future a significant effect on our operating results

when our operating results are translated into U.S.

dollars.

We are subject to anti-corruption laws, as well as export control

laws, customs laws, sanctions laws and other laws governing our

operations. If we fail to comply with these laws, it could be

subject to civil or criminal penalties, other remedial measures and

legal expenses, which could adversely affect our business, results

of operations and financial condition.

Our operations are subject to anti-corruption laws, including the

U.S. Foreign Corrupt Practices Act, or the FCPA, and other

anti-corruption laws that apply in countries where we do business

and may do business in the future. The FCPA and these other laws

generally prohibit us, our officers, and our employees and

intermediaries from bribing, being bribed or making other

prohibited payments to government officials or other persons to

obtain or retain business or gain some other business advantage. We

may in the future operate in jurisdictions that pose a high risk of

potential FCPA violations, and we may participate in collaborations

and relationships with third parties whose actions could

potentially subject us to liability under the FCPA or local

anti-corruption laws. We are also subject to other laws and

regulations governing our international operations, including

regulations administered by the government of the United States and

authorities in the European Union, including applicable export

control regulations, economic sanctions on countries and persons,

customs requirements and currency exchange regulations,

collectively referred to as the Trade Control laws. There is no

assurance that we will be completely effective in ensuring our

compliance with all applicable anti-corruption laws, including the

FCPA or other legal requirements, including Trade Control laws. If

we are not in compliance with the FCPA and other anti-corruption

laws or Trade Control laws, we may be subject to criminal and civil

penalties, disgorgement and other sanctions and remedial measures,

and legal expenses, which could have an adverse impact on our

business, financial condition, results of operations and liquidity.

Likewise, any investigation of any potential violations of the

FCPA, other anti-corruption laws or Trade Control laws by U.S. or

other authorities could also have an adverse impact on our

reputation, our business, results of operations and financial

condition.

Our employees, principal investigators, consultants and commercial

partners may engage in misconduct or other improper activities,

including noncompliance with regulatory standards and requirements

and insider trading, which could cause significant liability for us

and harm our reputation.

We are exposed to the risk of fraud or other misconduct by our

employees, principal investigators, consultants and collaborators,

including intentional failures to comply with FDA or Office of

Inspector General regulations or similar regulations of comparable

non-U.S. regulatory authorities, provide accurate information to

the FDA or comparable non-U.S. regulatory authorities, comply with

manufacturing standards we have established, comply with federal

and state healthcare fraud and abuse laws and regulations and

similar laws and regulations established and enforced by comparable

non-U.S. regulatory authorities, report financial information or

data accurately or disclose unauthorized activities to us.

Misconduct by these parties could also involve the improper use of

information obtained in the course of clinical trials, which could

result in regulatory sanctions and serious harm to our reputation.

It is not always possible to identify and deter misconduct, and the

precautions we take to detect and prevent this activity may not be

effective in controlling unknown or unmanaged risks or losses or in

protecting us from governmental investigations or other actions or

lawsuits stemming from a failure to be in compliance with such

laws, standards or regulations. If any such actions are instituted

against us, and we are not successful in defending ourselves or

asserting our rights, those actions could have a significant impact

on our business and results of operations, including the imposition

of significant fines or other sanctions.

We rely significantly on information technology and any failure,

inadequacy, interruption or security lapse of that technology,

including any cyber security incidents, could harm our ability to

operate our business effectively.

Despite the implementation of security measures, our internal

computer systems and those of third parties with which we contract

are vulnerable to damage from cyber-attacks, computer viruses,

unauthorized access, natural disasters, terrorism, war and

telecommunication and electrical failures. System failures,

accidents or security breaches could cause interruptions in our

operations, and could result in a material disruption of ours

clinical and commercialization activities and business operations,

in addition to possibly requiring substantial expenditures of

resources to remedy. The loss of clinical trial data could result

in delays in our regulatory approval efforts and significantly

increase our costs to recover or reproduce the data. To the extent

that any disruption or security breach were to result in a loss of,

or damage to, our data or applications, or inappropriate disclosure

of confidential or proprietary information, we could incur

liability and our product research, development and

commercialization efforts could be delayed.

18

The wind down of our Stellar subsidiary’s legacy business may

not deliver the expected results or may create unexpected

liabilities.

Following the business combination completed in June 2019, we

refocused our business on the development of innovative

therapeutics for inflammatory and immune-related diseases. Since

then, we have implemented plans to sell off or wind down the

principal assets and operations of our Stellar subsidiary’s

legacy business, which includes product inventory. We cannot be

sure that the sale and wind down of Stellar’s operations will

eliminate costs related to the legacy business; or result in any

unplanned expenditures or unknown, contingent or other liabilities,

including litigation arising in connection with legacy operations

or sales of Stellar’s product inventory. If our plans do not

achieve the expected results, our business and results of

operations will be adversely impacted.

Risks Related to Clinical Development, Regulatory Approval and

Commercialization

If clinical trials of our product candidates fail to demonstrate

safety and efficacy to the satisfaction of the FDA, Health Canada

(HC) or the European Medicines Agency (EMA), or do not otherwise

produce favorable results, we may incur additional costs or

experience delays in completing, or ultimately be unable to

complete, the development and commercialization our product

candidates.

In connection with obtaining marketing approval from regulatory

authorities for the sale of any product candidate, we must complete

preclinical development and then conduct extensive clinical trials

to demonstrate the safety and efficacy of our product candidates in

humans. Clinical trials are expensive, difficult to design and

implement, can take many years to complete and are uncertain as to

outcome. A failure of one or more clinical trials can occur at any

stage of testing. The outcome of preclinical testing and early

clinical trials may not be predictive of the success of later

clinical trials. In particular, the small number of subjects and

patients in early clinical trials of our product candidates may

make the results of these clinical trials less predictive of the

outcome of later clinical trials. The design of a clinical trial

can determine whether our results will support approval of a

product, and flaws in the design of a clinical trial may not become

apparent until the clinical trial is well advanced or completed.

There is no assurance that we will be able to design and execute a

clinical trial to support marketing approval. Moreover, preclinical

and clinical data are often susceptible to varying interpretations

and analyses, and many companies that have believed their product

candidates performed satisfactorily in preclinical studies and

clinical trials have nonetheless failed to obtain marketing

approval of their products.

Positive results in pre-clinical studies of a product candidate may

not be predictive of similar results in humans during clinical

trials, and promising results from early clinical trials of a

product candidate may not be replicated in later clinical trials. A

number of companies in the pharmaceutical and biotechnology

industries have suffered significant setbacks in late-stage

clinical trials even after achieving promising results in

early-stage development. Accordingly, the results from completed

pre-clinical studies and clinical trials for our product candidates

may not be predictive of the results we may obtain in later stage

trials or studies. Pre-clinical studies or clinical trials may

produce negative or inconclusive results, and we may decide, or

regulators may require us, to conduct additional pre-clinical

studies or clinical trials, or to discontinue clinical trials

altogether. Ultimately, we may be unable to complete the

development and commercialization of any of our product

candidates.

Interim results, top-line, initial data may not accurately reflect

the complete results of a particular study or trial.

We may publicly disclose interim, top-line or initial data from

time to time that is based on a preliminary analysis of

then-available efficacy and safety data, and the results and

related findings and conclusions are subject to change following a

more comprehensive review of the data related to the particular

study or trial. We also make assumptions, estimates, calculations

and conclusions as part of our analyses of data, and we may not

have received or had the opportunity to fully evaluate all data.

Interim, top-line and initial data should be viewed with caution

until the final data are available. In addition, the information we

may publicly disclose regarding a particular preclinical or

clinical study is based on what is typically extensive information,

and you or others may not agree with what we determine is the

material or otherwise appropriate information to include in our

disclosure, and any information we determine not to disclose may

ultimately be deemed significant with respect to future decisions,

conclusions, views, activities or otherwise regarding a particular

drug, drug candidate or our business. If the interim, top-line or

initial data that we report differ from actual results, or if

others, including regulatory authorities, disagree with the

conclusions reached, our ability to obtain approval for, and

commercialize, our product candidates may be harmed or delayed,

which could harm our business, financial condition, operating

results or prospects.

19

If clinical trials for our product candidates are prolonged or

delayed, we may be unable to commercialize our product candidates

on a timely basis, which would require us to incur additional costs

and delay our receipt of any revenue from potential product

sales.

We cannot predict whether we will encounter problems with any of

our ongoing or planned clinical trials that will cause us or any

regulatory authority to delay or suspend those clinical trials. A

number of events, including any of the following, could delay the

completion of our ongoing and planned clinical trials and

negatively impact our ability to obtain regulatory approval for,

and to market and sell, a particular product

candidate:

conditions imposed by the FDA or any foreign regulatory authority

regarding the scope or design of our clinical trials;

delays in obtaining, or the inability to obtain, required approvals

from institutional review boards, or IRBs, or other reviewing

entities at clinical sites selected for participation in our

clinical trials;

insufficient supply or deficient quality of product candidates

supply or materials to produce our product candidates or other

materials necessary to conduct our clinical trials;

delays in obtaining regulatory agreement for the conduct of the

clinical trials;

lower than anticipated enrollment and retention rate of subjects in

clinical trials for a variety of reasons, including size of patient

population, nature of trial protocol, the availability of approved

effective treatments for the relevant disease and competition from

other clinical trial programs for similar indications;

serious and unexpected drug-related side effects experienced by

patients in clinical trials;

failure of third-party contractors to meet their contractual

obligations in a timely manner;

pre-clinical or clinical trials may produce negative or

inconclusive results, which may require us or any potential future

collaborators to conduct additional pre-clinical or clinical

testing or to abandon projects that we expect to be

promising;

even if pre-clinical or clinical trial results are positive, the

FDA or foreign regulatory authorities could nonetheless require

unanticipated additional clinical trials;

regulators or institutional review boards may suspend or terminate

clinical research for various reasons, including noncompliance with

regulatory requirements;

product candidates may not have the desired effects;

and

the lack of adequate funding to continue clinical

trials.

Additionally, changes in standard of care or regulatory

requirements and guidance may occur and we may need to amend

clinical trial protocols to reflect these changes. Such amendments

may require us to resubmit our clinical trial protocols to IRBs for

re-examination, which may impact the cost, timing or successful

completion of a clinical trial. Such changes may also require us to

reassess the viability of the program in question.

We do not know whether our clinical trials will begin as planned,

will need to be restructured or will be completed on schedule, if

at all. Delays in clinical trials will result in increased

development costs for our product candidates. In addition, if we

experience delays in completion of, or if we terminate, any of our

clinical trials, the commercial prospects for our product

candidates may be affected and our ability to generate product

revenues will be delayed. Furthermore, many of the factors that

cause, or lead to, a delay in the commencement or completion of

clinical trials may also ultimately lead to the denial of

regulatory approval of a product candidate.

The clinical trial designs, endpoints and outcomes that will be

required to obtain marketing approval for our drug candidates are

uncertain. We may never receive marketing approval for our drug

candidates.

To our knowledge, there are currently no FDA-approved drug

treatment options specifically approved for many of the disease

indications we are targeting with our drug candidates. Accordingly,

there may not be well-established development paths and outcomes.

The FDA, Health Canada or any other regulatory authority outside of

the United States may determine that the designs or endpoints of

any trial that we conduct, or that the outcome shown on any

particular endpoint in any trial that we conduct, are not

sufficient to establish a clinically meaningful benefit for our

drug candidates, or otherwise, to support approval, even if the

primary endpoint(s) of the trial is met with statistical

significance. If this occurs, our business could be materially

harmed. Moreover, if the regulatory authorities require us to

conduct additional clinical trials beyond the ones that we

currently contemplate, our finances and results from operations

will be adversely impacted. If our clinical studies meet their

respective primary endpoints, we plan to request an end of Phase 2

meeting with the regulators and/or seek marketing approval. We

cannot predict whether each of these regulatory agencies will agree

that our study data and information will be sufficient to meet the

requirements for filing a marketing application or the standards

for approval. If the regulatory agencies determine that more data

and information are needed, it could delay and/or negatively impact

our ability to obtain regulatory approval to market and sell a

particular product candidate.

20

If the commercial opportunity in chronic ACD or COVID-19-induced

ARDS is smaller than we anticipate, our future revenue from EB01 or

EB05, as applicable, will be adversely affected and our business

will suffer.

It is critical to our ability to grow and become profitable that we

successfully identify patients with chronic ACD or COVID-19-induced

ARDS. Our projections of the number of people who have these

conditions as well as the subset who have the potential to benefit

from treatment with EB01 or EB05, are based on a variety of

sources, including third-party estimates and analyses in the

scientific literature, and may prove to be incorrect. Further, new

information may emerge that changes our estimate of the prevalence

of these diseases or the number of patient candidates for these

drug candidates. The effort to identify patients for our other

potential target indications is at an early stage, and we cannot

accurately predict the number of patients for whom treatment might

be possible. Additionally, the potentially addressable patient

population for our drug candidates may be limited or may not be

amenable to treatment with our drug candidates, and new patients

may become increasingly difficult to identify or access. If the

commercial opportunity for these conditions is smaller than we

anticipate, our future financial performance may be adversely

impacted.

While we have chosen to test our product candidates in specific

clinical indications based in part on our understanding of their

mechanisms of action, our understanding may be incorrect or

incomplete and, therefore, our product candidates may not be

effective against the diseases tested in our clinical

trials.

Our rationale for selecting the particular therapeutic indications

for each of our product candidates is based in part on our

understanding of the mechanism of action of these product

candidates. However, our understanding of the product

candidates’ mechanism of action may be incomplete or

incorrect, or the mechanism may not be clinically relevant to the

diseases treated. In such cases, our product candidates may prove

to be ineffective in the clinical trials for treating those

diseases, and adverse clinical trial results would likely

negatively impact our business and results from

operations.

A successful

sPLA2 drug has not been developed to date

and we can provide no assurances that we will be successful or that

there will be no adverse side effects.

Our sPLA2 product candidates employ a novel

mechanism of action. To our knowledge no drug companies have

successfully commercialized an sPLA2 inhibitor and as a result the efficacy

and long-term side effects are not known. There is no guarantee

that we will successfully develop and/or commercialize an

sPLA2 inhibitor and/or that our product

candidates will have no adverse side effects.

Even if one of our product candidates receives marketing approval,

it may fail to achieve the degree of market acceptance by

physicians, patients, third-party payors and others in the medical

community necessary for commercial success.

If any product candidate receives marketing approval, the approved

product may nonetheless fail to gain sufficient market acceptance

by physicians, patients, third-party payors and others in the

medical community. If an approved product does not achieve an

adequate level of acceptance, we may not generate significant

product revenues or any profits from operations. Our ability to

Source: SEC EDGAR (public domain) · 10-K for the period ended 2020-09-30, filed 2020-12-07 · accession 0001654954-20-013236

Filing HTML rendered to line-structured narrative text by the shipped reducer (datafeeds.edgar_fulltext.visible_text, keep_table_headers=True): scripts and inline-XBRL headers are dropped, and table content is reduced to its short label cells — numeric table data is not rendered and is therefore not counted. The same rendering is used for every year, so a year-over-year comparison is like for like.

The text is our rendering of the filing, not a facsimile: original pagination, typography and tables are not reproduced, and the numbers live in the financial statements (FA).

The outline locates item HEADINGS in this document. Only Items 1A and 7 have certified boundaries elsewhere in the terminal (the redline and the narrative-overlap number); every span here runs from one heading found to the next heading found.

How the outline was chosen. It is the longest chain of item headings that runs forward through both the document and the standard item order: 19 headings are on that chain and 2 further heading-shaped lines are not — the table-of-contents echo of every item, cross-references and exhibit-list mentions. Each entry's length is measured from its heading to the next heading on the chain.